NASDAQ$QURE
uniQure NV · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
uniQure reported financial results for 2022 and highlighted recent progress across its business.
uniQure had a strong ending to 2022 with the approval of the world’s first gene therapy for hemophilia B. The company is working to advance AMT-130 and preparing for the initiation of two new Phase I/II studies in refractory temporal lobe epilepsy and SOD1-ALS.
- Achieved U.S. and European Commission marketing approvals of first and only gene therapy for adults with hemophilia B
- Advancing development of AMT-130 for patients with Huntington’s disease – clinical update from U.S. Phase I/II trial expected in second quarter 2023
- Hosted virtual investor event featuring AMT-260 in refractory temporal lobe epilepsy - expected to enter clinical development in second half of 2023
- Expanded pipeline with in-licensing of AMT-162 for SOD1 ALS - plans to initiate a Phase I/II clinical trial in the second half of 2023
Headline financials
Revenue & EPS history
uniQure · Revenue · Quarterly
$103M
Forward guidance
uniQure provided forward-looking statements regarding their clinical trials and regulatory submissions.
Tailwinds
- AMT-130 clinical trial for Huntington’s Disease will begin enrollment in the U.S. in the second half of 2023
- The Company will announce one to two-years of follow up data from the U.S. Phase I/II clinical study of AMT-130 in the second quarter of 2023
- Clinical data from the lower-dose cohort for AMT-130 is expected to be presented in the second half of 2023
- The Company will submit an investigational new drug application for Fabry disease in 2023
- The company will initiate a Phase I/II clinical study of AMT-162 for the treatment of ALS in the second half of 2023
Headwinds
- Risks associated with the regulatory approval and commercial launch of HEMGENIX®
- Risks associated with our clinical trial for Huntington’s disease
- Impact of financial and geopolitical events on our Company and the wider economy and health care system
- Risks associated with our Commercialization and License Agreement with CSL Behring
- Risks associated with our clinical development activities, clinical results, collaboration arrangements, regulatory oversight, product commercialization and intellectual property claims
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.6%
Avg return
30 days after
59%
27 / 46 earnings
Positive
+47.1%
Q2 2015
Best reaction
-32.7%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | +34.0% | +35.5% | |
| Q4 2025 | -32.7% | -8.7% | +8.1% | |
| Q3 2025 | -6.0% | +7.5% | -27.5% | |
| Q1 2025 | +3.3% | +17.0% | +15.8% | |
| Q4 2024 | +3.4% | -2.9% | +6.9% | |
| Q3 2024 | +28.8% | +40.1% | +18.5% | |
| Q2 2024 | -4.6% | -1.3% | -23.6% | |
| Q1 2024 | +3.6% | +4.2% | +12.5% | |
| Q4 2023 | -14.8% | -23.6% | -23.0% | |
| Q3 2023 | +6.5% | -0.8% | +19.5% | |
| Q2 2023 | -3.0% | -9.2% | -16.0% | |
| Q1 2023 | +2.7% | +1.2% | -3.8% | |
| Q4 2022 | +5.0% | +6.2% | +1.3% | |
| Q3 2022 | +4.4% | +0.1% | +38.2% | |
| Q2 2022 | -25.5% | -20.2% | -18.4% | |
| Q1 2022 | +6.6% | -2.0% | -5.2% | |
| Q4 2021 | +5.9% | +13.0% | +4.5% | |
| Q3 2021 | -0.3% | +7.1% | +2.2% | |
| Q2 2021 | +8.5% | +11.5% | +10.7% | |
| Q1 2021 | +0.7% | -0.3% | +12.3% | |
| Q4 2020 | -2.0% | -11.5% | -8.2% | |
| Q3 2020 | -10.6% | -7.0% | +7.0% | |
| Q2 2020 | +10.7% | +12.0% | +3.7% | |
| Q1 2020 | +1.0% | -3.2% | +6.6% | |
| Q4 2019 | +1.5% | +1.4% | -11.3% | |
| Q3 2019 | -0.8% | +3.9% | +13.4% | |
| Q2 2019 | -8.5% | -9.1% | -17.1% | |
| Q1 2019 | -2.0% | +2.4% | +5.4% | |
| Q4 2018 | +7.7% | +11.8% | +12.1% | |
| Q3 2018 | +9.0% | +0.5% | +20.1% | |
| Q2 2018 | +6.6% | +9.3% | +21.9% | |
| Q1 2018 | -0.3% | -3.2% | +15.7% | |
| Q4 2017 | -13.5% | -17.2% | +16.9% | |
| Q3 2017 | -2.6% | +4.4% | +4.4% | |
| Q2 2017 | +7.2% | +5.1% | +4.8% | |
| Q1 2017 | +2.3% | +3.3% | +6.6% | |
| Q4 2016 | +1.0% | -3.1% | -10.5% | |
| Q3 2016 | -6.2% | -3.9% | -20.6% | |
| Q1 2016 | +11.8% | +16.8% | -38.5% | |
| Q3 2015 | -12.0% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q2 2015 | +47.1% | — | — | |
| Q4 2014 | -7.5% | — | — | |
| Q2 2014 | +10.9% | — | — | |
| Q4 2013 | +3.0% | — | — | |
| Q1 2014 | +0.4% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro